Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Argent Biopharma ( (AU:RGT) ) has provided an announcement.
Argent Biopharma Limited has notified the ASX of its intention to issue up to 20 million new fully paid ordinary shares in a proposed placement, with an expected issue date of 16 March 2026. The additional securities, to be quoted on the ASX subject to the exchange’s agreement, represent a capital-raising move that is likely aimed at strengthening the company’s balance sheet and providing funding flexibility for its ongoing biopharmaceutical activities, with potential implications for existing shareholders through equity dilution and for the company’s capacity to advance its pipeline.
The most recent analyst rating on (AU:RGT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
More about Argent Biopharma
Argent Biopharma Limited, listed on the ASX under the code RGT, operates in the biopharmaceutical sector, focusing on the development and commercialisation of healthcare and biotechnology-related products. The company accesses public equity markets to support its capital needs and advance its operational and R&D objectives.
Average Trading Volume: 79,171
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$5.42M
Find detailed analytics on RGT stock on TipRanks’ Stock Analysis page.